Long-term Omalizumab Therapy in Patients with Chronic Spontaneous Urticaria: Does it Increase the Risk of COVID-19?

• Váldodahkkit: Özge Kaya (Dahkki), Zeynep Keskinkaya (Dahkki), Selda Işık Mermutlu (Dahkki), Sevilay Oğuz Kılıç (Dahkki), Sevgi Öztürk (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Mattioli1885, 2023-07-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Introduction: Based on the existing literature, omalizumab (OMZ) is considered a safe treatment modality in chronic spontaneous urticaria (CSU) during the coronavirus disease 19 (COVID-19) era.  Objectives: The aim of this study is to evaluate the effects of OMZ on CSU patients regarding COVID-19 in...